MUMBAI (Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) cleared its Halol drug plant, which had been under supply restrictions due to quality control failures.
The FDA issued the company with a warning letter that year following an inspection that revealed manufacturing quality failures at Halol.
The company has been working on fixing problems the agency identified. The FDA inspected the plant again in February.
"The agency concluded that the inspection is now closed and the issues contained in the Warning Letter issued in December 2015 have been addressed," Sun said in a statement.
(Reporting by Zeba Siddiqui in Mumbai; editing by Jason Neely)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)